King & Spalding’s London office advised leading pharmaceutical company GSK on the transfer of its portfolio of approved and investigational rare disease gene therapies to Orchard Therapeutics Limited.

Under the agreement, GSK will become an investor in Orchard Therapeutics, receiving a 19.9% equity stake along with a seat on the company’s board. GSK will also receive financial consideration in the form of royalties and milestone payments on the acquired portfolio.

King & Spalding’s team on the deal was led by London corporate partner Marcus Young and included corporate associate Kelly Nash. Other lawyers on the team included London partners Jules Quinn (employment) and Daniel Friel (tax) and counsel Kim Roberts (data privacy). Atlanta-based partner Zach Cochran and associate Ben Massey provided securities advice.